SVB Securities analyst Faisal Khurshid reiterated a Hold rating on Rain Therapeutics (RAIN – Research Report) yesterday and set a price target of $2.00. The company’s shares closed yesterday at $1.09.
Khurshid covers the Healthcare sector, focusing on stocks such as Rain Therapeutics, Fusion Pharmaceuticals, and POINT Biopharma Global. According to TipRanks, Khurshid has an average return of 6.2% and a 69.23% success rate on recommended stocks.
In addition to SVB Securities, Rain Therapeutics also received a Hold from Roth MKM’s Kumaraguru Raja in a report issued yesterday. However, on May 22, Mizuho Securities maintained a Buy rating on Rain Therapeutics (NASDAQ: RAIN).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $14.48 and a one-year low of $0.94. Currently, Rain Therapeutics has an average volume of 1.09M.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RAIN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rain Therapeutics Inc is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. Its lead product candidate, RAIN-32 is a small molecule, oral inhibitor of mouse double minute 2, which is oncogenic in numerous cancers.
Read More on RAIN:
- Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
- Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3
- Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma
- Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress
